Xavier Leroy

Xavier Leroy

Company: Domain Therapeutics

Job title: CSO


Strategies & Successes to Discover Antibodies as the Next Potential Modality Towards Drugging GPCRs 11:30 am

Expanding modality selection for greater receptor immunogenicity and functionality Developing novel tools for high-throughput sampling and miniaturization of assays to effectively screen for functional antibodiesRead more

day: Day Two

Panel Discussion: The Future of Biologics to Develop Next Generation GPCR-Targeted Therapeutics 9:00 am

Biologics offer great potential in developing therapeutics targeting GPCRs due to their high affinity, selectivity, and long half-life. While many antibodies to GPCRs are in clinical trials and two antibodies have been FDA approved, further effort is needed to promote the rate of advancement of biologics targeting GPCRs. We will discuss the current challenges and…Read more

day: Day Two

Panel Discussion: Leveraging Human Genetics for Hit-to-Lead Optimization & Effective GPCRTarget Discovery 2:30 pm

Creating target discovery platforms based on genetic human data for better hit-to-lead optimization is at the forefront of early drug discovery pipelines across biotech and pharma industries. We will explore the learnings from Regeneron’s key candidate GPR75 and how to inform, develop and expedite the drug discovery process for clinical success. Leveraging the UK Biobank…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.